Intrexon | XON - Interest Expense On Debt


Intrexon reported $2K in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Agenus USD 14.67M 1.35M Mar/2026
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Amgen USD 95.64B 94.98B Jun/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
AstraZeneca USD 340M 144M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Gilead Sciences USD 247M 7M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Incyte USD 582K 13K Jun/2026
Intrexon USD 2K 5K Jun/2024
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
MacroGenics USD 4.89M 1.55M Mar/2026
MannKind USD 14.82M 2.38M Jun/2026
Merck USD 525M 46M Jun/2026
Novartis USD 462M 119M Jun/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Thermo Fisher Scientific USD 354M 11M Mar/2026
Veracyte USD 2K 1000 Dec/2023
Xencor USD 7.35M 2.65M Jun/2026